RT Journal Article
SR Electronic
T1 A Worldwide Study of White Matter Microstructural Alterations in People Living with Parkinson’s Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.16.24301235
DO 10.1101/2024.01.16.24301235
A1 Owens-Walton, Conor
A1 Nir, Talia M.
A1 Al-Bachari, Sarah
A1 Ambrogi, Sonia
A1 Anderson, Tim J.
A1 Aventurato, Ítalo Karmann
A1 Cendes, Fernando
A1 Chen, Yao-Liang
A1 Ciullo, Valentina
A1 Cook, Phil
A1 Dalrymple-Alford, John C.
A1 Dirkx, Michiel F.
A1 Druzgal, Jason
A1 Emsley, Hedley C. A.
A1 Guimarães, Rachel
A1 Haroon, Hamied A.
A1 Helmich, Rick C.
A1 Hu, Michele T.
A1 Johansson, Martin E.
A1 Kim, Ho Bin
A1 Klein, Johannes C.
A1 Laansma, Max
A1 Lawrence, Katherine E.
A1 Lochner, Christine
A1 Mackay, Clare
A1 McMillan, Corey
A1 Melzer, Tracy R.
A1 Nabulsi, Leila
A1 Newman, Ben
A1 Opriessnig, Peter
A1 Parkes, Laura M.
A1 Pellicano, Clelia
A1 Piras, Fabrizio
A1 Piras, Federica
A1 Pirpamer, Lukas
A1 Pitcher, Toni L.
A1 Poston, Kathleen L.
A1 Roos, Annerine
A1 Silva, Lucas Scárdua
A1 Schmidt, Reinhold
A1 Schwingenschuh, Petra
A1 Shahid, Marian
A1 Spalletta, Gianfranco
A1 Stein, Dan J.
A1 Thomopoulos, Sophia I.
A1 Tosun, Duygu
A1 Tsai, Chih-Chien
A1 van den Heuvel, Odile A.
A1 van Heese, Eva
A1 Vecchio, Daniela
A1 Villalón-Reina, Julio E.
A1 Vriend, Chris
A1 Wang, Jiun-Jie
A1 Wu, Yih-Ru
A1 Yasuda, Clarissa Lin
A1 Thompson, Paul M.
A1 Jahanshad, Neda
A1 van der Werf, Ysbrand
YR 2024
UL http://medrxiv.org/content/early/2024/01/17/2024.01.16.24301235.abstract
AB Background The progression of Parkinson’s disease (PD) is associated with microstructural alterations in neural pathways, contributing to both motor and cognitive decline. However, conflicting findings have emerged due to the use of heterogeneous methods in small studies, particularly regarding the involvement of white matter (WM) tracts. Here we performed the largest diffusion MRI study of PD to date, integrating data from 17 cohorts worldwide, to identify stage-specific profiles of WM differences.Methods Diffusion-weighted MRI data from 1,654 participants diagnosed with PD (age range: 20-89 years; 33% female) and 885 controls (age range: 19-84 years; 47% female) were analyzed using the ENIGMA-DTI protocol to evaluate regional microstructure in 21 white matter regions. Skeletonized maps of diffusion tensor imaging fractional anisotropy (FA) and mean diffusivity (MD) were analyzed and compared between Hoehn and Yahr (HY) disease groups and controls to reveal the profile of white matter differences at different stages.Results We found an enhanced, more widespread pattern of microstructural differences with each stage of PD, with eventually lower FA and higher MD in almost all regions of interest (ROIs): Cohen’s d effect sizes reached d=-1.01 for FA differences in the fornix by PD HY Stage 4/5. The early PD signature in HY stages 1 and 2 included higher FA and lower MD across the entire white matter skeleton, in a direction opposite to that typical of other neurodegenerative diseases. FA and MD were associated with clinical metrics of motor and non-motor clinical dysfunction.Conclusion While overridden by degenerative changes in the later stages of PD, early PD is associated with paradoxically higher FA in PD, which is consistent with early compensatory changes associated with the disorder.Competing Interest StatementNJ was MPI of a research grant from Biogen Inc for work unrelated to the contents of this manuscript. In the past 3 years, DS has received consultancy honoraria from Discovery Vitality, Johnson & Johnson, Kanna, LOreal, Lundbeck, Orion, Sanofi, Servier, Takeda and VistagenFunding StatementTA: Health Research Council of New Zealand (20/538; 21/165); IA: S&atildeo Paulo Research Foundation FAPESP BRAINN Grants# 2013075593 / FAPESP #2022 1178 4; FC: S&atildeo Paulo Research Foundation FAPESP BRAINN Grant # 2013 07559 3; JDA: Health Research Council of New Zealand (20/538); Marsden Fund New Zealand (UOC2105), Neurological Foundation of New Zealand (2232 PRG); Research and Education Trust Pacific Radiology (MRIJDA); MD: Grant from ParkinsonNL (P2023 14); Honoraria from Movement Disorders Society Quebec; JD: R01NS107513; HE: Engineering and Physical Sciences Research Council (EPSRC) UK; MH: Parkinsons UK, Cure Parkinsons Trust, Oxford Biomedical Research Centre, GSK Oxford IMCM; NJ: R01AG059874, R01MH117601, R01NS107513, R01AG058854, P41EB015922; JK: is supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), and the NIHR Oxford Health Clinical Research Facility. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health; JK: F32MH122057 from NIMH; CM: U19 AG062418; TM: Health Research Council of New Zealand (20/538); Neurological Foundation of New Zealand (2232 PRG); Research and Education Trust Pacific Radiology (MRIJDA); TN: U.S. Alzheimers Association (AARG 23 1149996); COW: R01NS107513; LP: Salary: University of Manchester; Grants: EPSRC UK, MRC UK, GE medical systems, Academy of Medical Sciences UK; FP: Italian Ministry of Health, grant number RF 2019 2370182; TP: Health Research Council of New Zealand (21/165); PS: reports personal fees from Bial, AbbVie and Boston Scientific; DT: NIH/NIA; JW: National Science and Technology Council, Taiwan (109 2314 B 182 021 MY3,109 2221 E 182 009 MY3); CY: S&atildeo Paulo Research Foundation FAPESP BRAINN Grant # 2013075593; CNPQ (#315953/2021 7) National Council for Scientific and Technological DevelopmentAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesOpen source datasets that support the findings of this study include PPMI and UK Biobank. Data for remaining cohorts are not openly available, but researchers are invited to register interest with the ENIGMA-PD Working Group in order to formally request site data through secondary proposals.